Skip to main content
Caplight Logo









Immugenia Inc.

Immugenia Inc.

Private
SherbrookeHealthcare & Life Scienceshttps://immugenia.com/

Last Round

Grant

Oct 15, 2024

Company Overview

Immugenia Inc. is a biotechnology company that develops immuno-oncology therapies by engineering hematopoietic stem cells to treat cancer and prevent relapses.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

immuno-oncologyCAR-T therapychimeric antigen receptorhematopoietic stem cellHSCsynthetic promotergene therapycell therapycancer immunotherapynext-gen CARNK cell therapyin vivo gene deliverysolid tumor treatmentbiotech licensingdrug discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Immugenia Inc. Comparables

Compare Immugenia Inc. with similar companies based on industry and business-model similarity.

Immugenia Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Ensoma
76%
EXUMA Biotech
73%
Chromatin Bioscience
73%

Immugenia Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantOct 15, 2024
Pre SeedOct 6, 2022

Key People

Founding team and executive leadership

Stéphane Gagné

Founder, President & CEO

Founding Team

Immugenia Inc. Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Oct 15, 2024

    $3M grant received from Brain Canada Foundation and others.

  • Oct 6, 2022

    Secured funding from adMare BioInnovations, Accélérateur de création d'entreprises technologiques, and Sherbrooke Innopole.

Immugenia Inc. Filings

Explore SEC and related filing metadata, where available.

Immugenia Inc. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Immugenia Inc.'s valuation, stock price, and market status.

Is Immugenia Inc. a public or private company?

Immugenia Inc. is a private company.

What is the current stock price of Immugenia Inc.?

Immugenia Inc. is a private company with no public stock price. Caplight tracks Immugenia Inc.'s secondary market activity and provides MarketPrice™ estimates to Caplight users.

How much is Immugenia Inc. worth (valuation)?

Valuation information for Immugenia Inc. is not publicly available.

Can I buy Immugenia Inc. stock?

Immugenia Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Immugenia Inc.'s last funding round?

Immugenia Inc.'s most recent funding round was Grant on October 15, 2024.

Who are the main investors in Immugenia Inc.?

Key investors in Immugenia Inc. include Brain Canada Foundation, Consortium Québécois sur la découverte du médicament, Accélérateur de création d'entreprises technologiques, adMare BioInnovations, Sherbrooke Innopole.

Will Immugenia Inc. IPO soon?

No public IPO plans have been announced for Immugenia Inc..

How can I track Immugenia Inc. secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Immugenia Inc.'s secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSherbrooke
Employee Range3
Year Founded2019
Last FundingOct 15, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?